Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Short-term Investments (2017 - 2025)

Lemaitre Vascular (LMAT) has disclosed Short-term Investments for 9 consecutive years, with $330.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 20.71% to $330.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $330.9 million, a 20.71% increase, with the full-year FY2025 number at $330.9 million, up 20.71% from a year prior.
  • Short-term Investments was $330.9 million for Q4 2025 at Lemaitre Vascular, up from $317.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $330.9 million in Q4 2025 to a low of $214000.0 in Q1 2021.
  • A 5-year average of $120.3 million and a median of $74.8 million in 2023 define the central range for Short-term Investments.
  • Biggest YoY gain for Short-term Investments was 26116.82% in 2021; the steepest drop was 98.91% in 2021.
  • Lemaitre Vascular's Short-term Investments stood at $56.1 million in 2021, then rose by 13.28% to $63.6 million in 2022, then increased by 27.14% to $80.8 million in 2023, then soared by 239.23% to $274.1 million in 2024, then grew by 20.71% to $330.9 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Short-term Investments are $330.9 million (Q4 2025), $317.6 million (Q3 2025), and $292.3 million (Q2 2025).